UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 232

Sortiert nach

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of oncology, 2023-01, Vol.34 (1), p.10-32

2023

Link zum Volltext

Verfügbarkeit prüfen

Practical considerations in screening for genetic alterations in cholangiocarcinoma

Annals of oncology, 2021-09, Vol.32 (9), p.1111-1126

2021

Link zum Volltext

Verfügbarkeit prüfen

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Annals of oncology, 2020-01, Vol.31 (1), p.30-40

2020

Link zum Volltext

Verfügbarkeit prüfen

Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?

Annals of oncology, 2021-11, Vol.32 (11), p.1311-1313

2021

Link zum Volltext

Verfügbarkeit prüfen

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

Annals of oncology, 2020-11, Vol.31 (11), p.1491-1505

2020

Link zum Volltext

Verfügbarkeit prüfen

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

Annals of oncology, 2022-08, Vol.33 (8), p.750-768

2022

Link zum Volltext

Verfügbarkeit prüfen

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

Annals of oncology, 2021-03, Vol.32 (3), p.337-350

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

Annals of oncology, 2014-09, Vol.25 (9), p.1756-1761

2014

Link zum Volltext

Verfügbarkeit prüfen

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

Annals of oncology, 2022-05, Vol.33 (5), p.466-487

2022

Link zum Volltext

Verfügbarkeit prüfen

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

Annals of oncology, 2018-01, Vol.29 (1), p.30-35

2018

Link zum Volltext

Verfügbarkeit prüfen

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

ESMO open, 2021-06, Vol.6 (3), p.100164-100164, Article 100164

2021

Link zum Volltext

Verfügbarkeit prüfen

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

Annals of oncology, 2018-01, Vol.29 (1), p.112-118

2018

Link zum Volltext

Verfügbarkeit prüfen

Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer

Annals of oncology, 2012-03, Vol.23 (3), p.597-604

2012

Link zum Volltext

Verfügbarkeit prüfen

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction

Cell death & disease, 2013-05, Vol.4 (5), p.e620-e620

2013

Link zum Volltext

Verfügbarkeit prüfen

Role of molecular genetics in the clinical management of cholangiocarcinoma

ESMO open, 2022-06, Vol.7 (3), p.100505-100505, Article 100505

2022

Link zum Volltext

Verfügbarkeit prüfen

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

Current drug targets, 2010-07, Vol.11 (7), p.851

2010

Link zum Volltext

Verfügbarkeit prüfen

Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

Oncology reports, 2013-05, Vol.29 (5), p.1763-1768

2013

Link zum Volltext

Verfügbarkeit prüfen

The ErbB receptors and their ligands in cancer: an overview

Current drug targets, 2005-05, Vol.6 (3), p.243

2005

Link zum Volltext

Verfügbarkeit prüfen

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

Endocrine-related cancer, 2003-03, Vol.10 (1), p.1-21

2003

Link zum Volltext

Verfügbarkeit prüfen

Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL

Virchows Archiv : an international journal of pathology, 2021-03, Vol.478 (3), p.553-565

2021

Link zum Volltext

Verfügbarkeit prüfen

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

British journal of cancer, 2014-07, Vol.111 (2), p.413-420

2014

Link zum Volltext

Verfügbarkeit prüfen

Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS

Annals of oncology, 2019-07, Vol.30, p.iv116-iv116

2019

Link zum Volltext

Verfügbarkeit prüfen

AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

Annals of oncology, 2018-10, Vol.29, p.viii30-viii30

2018

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 232

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(217)
Mit Volltextzugriff
(212)

Publikationsform

Artikel
(231)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(123)
Life Sciences & Biomedicine
(121)
Humans
(110)
Oncology
(77)
Biological And Medical Sciences
(58)
Animals
(46)
Female
(35)
Medical Sciences
(34)
Tumors
(33)
Intercellular Signaling Peptides And Proteins
(29)
Fundamental And Applied Biological Sciences. Psychology
(25)
Gpi-Linked Proteins
(25)
Epidermal Growth Factor
(21)
Mice
(19)
Amphiregulin
(18)
Membrane Glycoproteins
(18)
Egf Family Of Proteins
(17)
Neoplasm Proteins - Genetics
(17)
Tumor Cells, Cultured
(17)
Breast Neoplasms - Pathology
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Practical considerations in screening for genetic alterations in cholangiocarcinoma

Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives

Harmful cytokines in cancer immunology and immunotherapy: biomarkers and targets?

Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical research

Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial

ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer

The European Society for Medical Oncology (ESMO) Precision Medicine Glossary

The molecular profiling of solid tumors by liquid biopsy: a position paper of the AIOM–SIAPEC-IAP–SIBioC–SIC–SIF Italian Scientific Societies

Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial

RAS testing of liquid biopsy correlates with the outcome of metastatic colorectal cancer patients treated with first-line FOLFIRI plus cetuximab in the CAPRI-GOIM trial

Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: implications for adjuvant therapy of breast cancer

TGF-β1 exposure induces epithelial to mesenchymal transition both in CSCs and non-CSCs of the A549 cell line, leading to an increase of migration ability in the CD133+ A549 cell fraction

Role of molecular genetics in the clinical management of cholangiocarcinoma

Predictive biomarkers to tyrosine kinase inhibitors for the epidermal growth factor receptor in non-small-cell lung cancer

Prognostic value of cancer stem cells, epithelial-mesenchymal transition and circulating tumor cells in lung cancer

The ErbB receptors and their ligands in cancer: an overview

Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment

Biomarker testing in oncology – Requirements for organizing external quality assessment programs to improve the performance of laboratory testing: revision of an expert opinion paper on behalf of IQNPath ABSL

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials

Optimizing treatment with anti-epidermal growth factor receptor drugs for patients with metastatic colorectal cancer: novel mechanisms of resistance beyond RAS

AXL has a prognostic role in metastatic colorectal cancer (mCRC) and is a predictive biomarker of lack of efficacy of chemotherapy (CT) + cetuximab in RAS wild type (WT) patients (pts)

Suchergebnisse filtern